These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 31591533)

  • 21. Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia.
    Hosokawa K; Muranski P; Feng X; Townsley DM; Liu B; Knickelbein J; Keyvanfar K; Dumitriu B; Ito S; Kajigaya S; Taylor JG; Kaplan MJ; Nussenblatt RB; Barrett AJ; O'Shea J; Young NS
    J Immunol; 2016 Feb; 196(4):1568-78. PubMed ID: 26764034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner.
    Charlton JJ; Chatzidakis I; Tsoukatou D; Boumpas DT; Garinis GA; Mamalaki C
    J Immunol; 2013 Jun; 190(12):6104-14. PubMed ID: 23686498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The function and dysfunction of memory CD8
    Reading JL; Gálvez-Cancino F; Swanton C; Lladser A; Peggs KS; Quezada SA
    Immunol Rev; 2018 May; 283(1):194-212. PubMed ID: 29664561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
    Zhang F; Bai H; Gao R; Fei K; Duan J; Zhang Z; Wang J; Hu X
    Cancer Immunol Immunother; 2020 Dec; 69(12):2599-2611. PubMed ID: 32591861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
    Chow MT; Ozga AJ; Servis RL; Frederick DT; Lo JA; Fisher DE; Freeman GJ; Boland GM; Luster AD
    Immunity; 2019 Jun; 50(6):1498-1512.e5. PubMed ID: 31097342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early CD8 T-cell memory precursors and terminal effectors exhibit equipotent in vivo degranulation.
    Yuzefpolskiy Y; Baumann FM; Kalia V; Sarkar S
    Cell Mol Immunol; 2015 Jul; 12(4):400-8. PubMed ID: 25066419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR
    Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches.
    Dähling S; Mansilla AM; Knöpper K; Grafen A; Utzschneider DT; Ugur M; Whitney PG; Bachem A; Arampatzi P; Imdahl F; Kaisho T; Zehn D; Klauschen F; Garbi N; Kallies A; Saliba AE; Gasteiger G; Bedoui S; Kastenmüller W
    Immunity; 2022 Apr; 55(4):656-670.e8. PubMed ID: 35366396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
    D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
    J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade.
    Blackburn SD; Shin H; Freeman GJ; Wherry EJ
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15016-21. PubMed ID: 18809920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint blockade therapy.
    Wieder T; Eigentler T; Brenner E; Röcken M
    J Allergy Clin Immunol; 2018 Nov; 142(5):1403-1414. PubMed ID: 29596939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.